SYNT 001

Drug Profile

SYNT 001

Alternative Names: SYNT001

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Syntimmune
  • Class Immunotherapies
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Autoimmune disorders; Pemphigus

Most Recent Events

  • 04 Dec 2017 Applied BioMath and Syntimmune agree to support development of SYNT 001 for IgG-mediated autoimmune diseases
  • 01 Aug 2017 Syntimmune initiates enrolment in a phase I trial in Autoimmune disorders in USA (IV) (NCT03075878)
  • 01 Jul 2017 Phase-I/II clinical trials in Pemphigus in USA (IV) (NCT03075904; 9225810)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top